10.85
+0.22(+2.07%)
Currency In USD
| Previous Close | 10.63 |
| Open | 10.63 |
| Day High | 10.88 |
| Day Low | 10.3 |
| 52-Week High | 13.85 |
| 52-Week Low | 5.79 |
| Volume | 1.55M |
| Average Volume | 2.69M |
| Market Cap | 1.89B |
| PE | -7.59 |
| EPS | -1.43 |
| Moving Average 50 Days | 11.95 |
| Moving Average 200 Days | 9.58 |
| Change | 0.22 |
If you invested $1000 in Ocular Therapeutix, Inc. (OCUL) 10 years ago, it would be worth $1,051.36 as of November 10, 2025 at a share price of $10.85. Whereas If you bought $1000 worth of Ocular Therapeutix, Inc. (OCUL) shares 5 years ago, it would be worth $810.31 as of November 10, 2025 at a share price of $10.85.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Ocular Therapeutix™ Achieves Target Randomization of 555 Subjects in SOL-R
GlobeNewswire Inc.
Nov 04, 2025 12:00 PM GMT
SOL-R, the second registrational trial of AXPAXLI™ in wet AMD, remains on track for topline data in 1H 2027 Together with SOL-1, these complementary trials are expected to form the basis of a potential NDA submission for AXPAXLI in wet AMD BEDFORD, M
Ocular Therapeutix™ to Report Third Quarter 2025 Financial Results on November 4, 2025
GlobeNewswire Inc.
Oct 28, 2025 11:00 AM GMT
BEDFORD, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and
Ocular Therapeutix™ Announces Pricing of Underwritten Offering of Common Stock
GlobeNewswire Inc.
Sep 30, 2025 11:08 AM GMT
BEDFORD, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (Nasdaq: OCUL) (“Ocular”, the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced the pricing of an underwrit